Terminal complement inhibition dampens the inflammation during COVID‐19

Saved in:
Bibliographic Details
Published inBritish journal of haematology Vol. 190; no. 3; pp. e141 - e143
Main Authors Kulasekararaj, Austin G., Lazana, Ioanna, Large, Joanna, Posadas, Kristina, Eagleton, Helen, Lord Villajin, John, Zuckerman, Mark, Gandhi, Shreyans, Marsh, Judith C. W.
Format Journal Article
LanguageEnglish
Published England Blackwell Publishing Ltd 01.08.2020
John Wiley and Sons Inc
Subjects
Adult
Betacoronavirus
C5 inhibition
complement activation
Complement Activation - drug effects
Complement Inactivating Agents - pharmacology
Complement Inactivating Agents - therapeutic use
Coronavirus Infections - complications
Coronavirus Infections - drug therapy
Coronavirus Infections - immunology
Correspondence
COVID-19
COVID‐19 ‐ Online only
Female
Hematology
Hemoglobinuria, Paroxysmal - complications
Hemoglobinuria, Paroxysmal - drug therapy
Hemoglobinuria, Paroxysmal - immunology
Hemolysis - drug effects
Humans
Inflammation - drug therapy
Male
Middle Aged
Pandemics
paroxysmal nocturnal haemoglobinuria
Pneumonia, Viral - complications
Pneumonia, Viral - drug therapy
Pneumonia, Viral - immunology
SARS-CoV-2
COVID-19
complement activation
paroxysmal nocturnal haemoglobinuria
C5 inhibition
Online AccessGet full text

Cover

More Information
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0007-1048
1365-2141
DOI:10.1111/bjh.16916